THERMO FISHER SCIENTIFIC INC.
TMOAPI behind this page
TMO Q1 2026 request
Playground key active
/api/financials?ticker=TMO&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 11,005 | 10,364 | +6.2% |
Show Product Lines breakouts |
|||
| Consumables | 4,722 | 4,354 | +8.5% |
| Instruments | 1,555 | 1,626 | -4.4% |
| Product | 6,277 | 5,980 | +5.0% |
| Service | 4,728 | 4,384 | +7.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments | 1,667 | 1,677 | -0.6% |
| Analytical Instruments · Chemical analysis | 285 | 286 | -0.3% |
| Analytical Instruments · Chromatography and mass spectrometry | 798 | 773 | +3.2% |
| Analytical Instruments · Electron microscopy | 633 | 659 | -3.9% |
| Analytical Instruments · Material Reconciling Items | 49 | 41 | +19.5% |
| Analytical Instruments · Operating Segments | 1,716 | 1,718 | -0.1% |
| Laboratory Products and Biopharma Services | 5,995 | 5,603 | +7.0% |
| Laboratory Products and Biopharma Services · Clinical research | 2,128 | 1,939 | +9.7% |
| Laboratory Products and Biopharma Services · Intersubsegment Eliminations | -228 | -214 | -6.5% |
| Laboratory Products and Biopharma Services · Laboratory products | 569 | 582 | -2.2% |
| Laboratory Products and Biopharma Services · Material Reconciling Items | 41 | 37 | +10.8% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,036 | 5,640 | +7.0% |
| Laboratory Products and Biopharma Services · Pharma services | 1,741 | 1,607 | +8.3% |
| Laboratory Products and Biopharma Services · Research and safety market channel | 1,827 | 1,727 | +5.8% |
| Life Sciences Solutions | 2,219 | 1,954 | +13.6% |
| Life Sciences Solutions · BioProduction | 893 | 671 | +33.1% |
| Life Sciences Solutions · Biosciences | 981 | 993 | -1.2% |
| Life Sciences Solutions · Genetic sciences | 655 | 677 | -3.2% |
| Life Sciences Solutions · Material Reconciling Items | 417 | 387 | +7.8% |
| Life Sciences Solutions · Operating Segments | 2,636 | 2,341 | +12.6% |
| Life Sciences Solutions · Other | 107 | — | — |
| Specialty Diagnostics | 1,124 | 1,130 | -0.5% |
| Specialty Diagnostics · Clinical diagnostics | 271 | 263 | +3.0% |
| Specialty Diagnostics · Healthcare market channel | 430 | 474 | -9.3% |
| Specialty Diagnostics · ImmunoDiagnostics | 230 | 217 | +6.0% |
| Specialty Diagnostics · Intersubsegment Eliminations | -71 | -72 | +1.4% |
| Specialty Diagnostics · Material Reconciling Items | 18 | 18 | 0.0% |
| Specialty Diagnostics · Microbiology | 160 | 152 | +5.3% |
| Specialty Diagnostics · Operating Segments | 1,142 | 1,148 | -0.5% |
| Specialty Diagnostics · Transplant diagnostics | 121 | 113 | +7.1% |
Show Geography breakouts |
|||
| Asia Pacific | 1,970 | 1,891 | +4.2% |
| Europe | 2,957 | 2,624 | +12.7% |
| North America | 5,705 | 5,513 | +3.5% |
| Other regions | 372 | 337 | +10.4% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -524 | -482 | -8.7% |
| Material Reconciling Items | 524 | 482 | +8.7% |
| Operating Segments | 11,529 | 10,846 | +6.3% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 3,261 | 3,125 | +4.4% |
| Service | 3,314 | 3,004 | +10.3% |
| Selling, General & Administrative | 2,181 | 2,078 | +5.0% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 313 | 313 | 0.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 597 | 588 | +1.5% |
| Life Sciences Solutions · Operating Segments | 496 | 468 | +6.0% |
| Specialty Diagnostics · Operating Segments | 177 | 171 | +3.5% |
| Research & Development | 336 | 342 | -1.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 139 | 137 | +1.5% |
| Laboratory Products and Biopharma Services · Operating Segments | 15 | 13 | +15.4% |
| Life Sciences Solutions · Operating Segments | 131 | 139 | -5.8% |
| Specialty Diagnostics · Operating Segments | 44 | 45 | -2.2% |
| Restructuring And Other Costs Income Net | 49 | 98 | -50.0% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 4 | — | — |
| Laboratory Products and Biopharma Services · Operating Segments | 33 | — | — |
| Life Sciences Solutions · Operating Segments | 9 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 3 | — | — |
| Material Reconciling Items | 49 | 98 | -50.0% |
| Total Costs & Expenses | 9,142 | 8,648 | +5.7% |
| Operating Income | 1,863 | 1,716 | +8.6% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 355 | 399 | -11.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 778 | 731 | +6.4% |
| Life Sciences Solutions · Operating Segments | 954 | 834 | +14.4% |
| Specialty Diagnostics · Operating Segments | 313 | 304 | +3.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,399 | 2,269 | +5.7% |
| Interest Income | 233 | 203 | +14.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 233 | 203 | +14.8% |
| Interest Expense | -354 | -303 | -16.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -354 | -303 | -16.8% |
| Other Non-Operating Income (Expense) | -9 | 3 | -400.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -9 | 3 | -400.0% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 1,734 | 1,620 | +7.0% |
| Income Tax Expense (Benefit) | -70 | -95 | +26.3% |
| Income Loss From Equity Method Investments | -8 | -14 | +42.9% |
| Net Income | 1,656 | 1,511 | +9.6% |
| Net Income Loss Attributable To Noncontrolling Interest | 5 | 4 | +25.0% |
| Net Income | 1,651 | 1,507 | +9.6% |
| EPS (Basic) | 4.44 | 3.99 | +11.3% |
| EPS (Diluted) | 4.43 | 3.98 | +11.3% |
| Wtd Avg Shares (Basic) | 372 | 378 | -1.6% |
| Wtd Avg Shares (Diluted) | 373 | 379 | -1.6% |
| Cost of Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 876 | 835 | +4.9% |
| Laboratory Products and Biopharma Services · Operating Segments | 4,757 | 4,410 | +7.9% |
| Life Sciences Solutions · Operating Segments | 1,004 | 855 | +17.4% |
| Specialty Diagnostics · Operating Segments | 657 | 679 | -3.2% |
| Comprehensive Income | 1,602 | 1,861 | -13.9% |
| Gain Loss On Investments | -1 | 2 | -150.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,254 | 4,134 | -21.3% |
| Short-Term Investments | 2 | 1,813 | -99.9% |
| Accounts Receivable | 9,204 | 8,455 | +8.9% |
| Inventory | 5,496 | 5,224 | +5.2% |
| Contract With Customer Asset Net Current | 1,684 | 1,366 | +23.3% |
| Other Assets Current | 2,677 | 2,387 | +12.1% |
| Total Current Assets | 22,316 | 23,378 | -4.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 10,658 | 9,331 | +14.2% |
| Other Non-Current Assets | 5,973 | 4,516 | +32.3% |
| Goodwill | 55,187 | — | — |
| Total Assets | 113,281 | 99,041 | +14.4% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 3,104 | 2,986 | +4.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,921 | 6,467 | +7.0% |
| Life Sciences Solutions · Operating Segments | 3,490 | 3,018 | +15.6% |
| Specialty Diagnostics · Operating Segments | 1,332 | 1,298 | +2.6% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 98,434 | 85,272 | +15.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 19,146 | 15,323 | +24.9% |
| Current Liabilities | |||
| Debt Current | 3,090 | 2,819 | +9.6% |
| Accounts Payable | 3,344 | 3,049 | +9.7% |
| Employee Related Liabilities Current | 1,565 | 1,419 | +10.3% |
| Deferred Revenue (Current) | 2,928 | 2,866 | +2.2% |
| Other Liabilities Current | 3,694 | 3,022 | +22.2% |
| Total Current Liabilities | 14,621 | 13,174 | +11.0% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,107 | 1,041 | +102.4% |
| Other Non-Current Liabilities | 4,421 | 3,971 | +11.3% |
| Long-Term Debt | 42,947 | 33,989 | +26.4% |
Show Long-Term Debt Type breakouts |
|||
| Commercial Paper | 393 | — | — |
| Other | 1 | 74 | -98.6% |
| Senior Notes | 42,554 | 33,915 | +25.5% |
| Contract With Customer Liability Noncurrent | 1,034 | 1,127 | -8.3% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 40,071 | 31,370 | +27.7% |
| Redeemable Noncontrolling Interest Equity Carrying Amount | 121 | 128 | -5.5% |
| Stockholders' Equity | |||
| Common Stock | 445 | 444 | +0.2% |
| Additional Paid In Capital Common Stock | 18,713 | 18,111 | +3.3% |
| Retained Earnings | 60,632 | 54,447 | +11.4% |
| Treasury Stock Common Value | -25,360 | -21,269 | -19.2% |
| Accumulated Other Comprehensive Income | -2,497 | -2,343 | -6.6% |
| Total Stockholders' Equity | 51,934 | 49,390 | +5.2% |
| Minority Interest | 7 | -33 | +121.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 51,940 | 49,357 | +5.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -242 | -265 | +8.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -22 | -24 | +8.3% |
| Accumulated Other Comprehensive Income | -2,497 | -2,343 | -6.6% |
| Accumulated Translation Adjustment | -2,234 | -2,053 | -8.8% |
| Additional Paid In Capital | 18,713 | 18,111 | +3.3% |
| Common Stock | 445 | 444 | +0.2% |
| Noncontrolling Interest | 7 | -33 | +121.2% |
| Parent | 51,934 | 49,390 | +5.2% |
| Retained Earnings | 60,632 | 54,447 | +11.4% |
| Treasury Stock Common | -25,360 | -21,269 | -19.2% |
| Total Liabilities & Equity | 113,281 | 99,041 | +14.4% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 306 | 276 | +10.9% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 26 | 24 | +8.3% |
| Laboratory Products and Biopharma Services · Operating Segments | 186 | 172 | +8.1% |
| Life Sciences Solutions · Operating Segments | 70 | 59 | +18.6% |
| Specialty Diagnostics · Operating Segments | 24 | 22 | +9.1% |
| Amortization Of Intangible Assets | 430 | 429 | +0.2% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 430 | 429 | +0.2% |
| Deferred Income Taxes | -258 | -279 | +7.5% |
| Stock-Based Compensation | 83 | 75 | +10.7% |
| Other Non-Cash Items | 88 | 135 | -34.8% |
| Increase Decrease In Operating Capital Excluding Deferred Taxes | -1,112 | -1,425 | +22.0% |
| Net Cash from Operations | 1,192 | 723 | +64.9% |
| Investing Activities | |||
| Capital Expenditures | -376 | -362 | -3.9% |
| Proceeds From Sale Of Property Plant And Equipment | 9 | 12 | -25.0% |
| Proceeds From Payments For Cross Currency Interest Rate Swap Interest Settlements | 96 | 87 | +10.3% |
| Payments To Acquire Businesses Net Of Cash Acquired | -8,872 | — | — |
| Payments To Acquire Investments | -14 | -264 | +94.7% |
| Proceeds From Sale Maturity And Collections Of Investments | 250 | 2 | +12400.0% |
| Other Investing Activities | -55 | -1 | -5400.0% |
| Net Cash from Investing | -8,961 | -527 | -1600.4% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 5,238 | 2,840 | +84.4% |
| Repayments Of Long Term Debt | -1,412 | -838 | -68.5% |
| Proceeds From Issuance Of Commercial Paper | 389 | — | — |
| Share Repurchases | -3,000 | -2,000 | -50.0% |
| Payments Of Dividends Common Stock | -162 | -149 | -8.7% |
| Proceeds From Payments For Other Financing Activities | 39 | 45 | -13.3% |
| Net Cash from Financing | 1,093 | -102 | +1171.6% |
| Supplemental | |||
| Unpaid Capital Expenditures | 206 | 173 | +19.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 78 | 37 | +110.8% |
| Net Change in Cash | -6,599 | 132 | -5099.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,280 | 4,172 | -21.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.